CardioMech MVRS
DeviceCardioMech MVRS
NCT Number: NCT04820764
Safety and performance evaluation of the CardioMech Mitral Valve Repair System (MVRS) in patients with degenerative mitral valve regurgitation.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Cardiovascular Institute of Los Robles Health System, Thousand Oaks, California, United States
The purpose of the clinical study is to obtain clinical data on the CardioMech Mitral Valve Repair System (MVRS) in patients diagnosed with moderate to severe (≥3+) or severe (≥4+), symptomatic, degenerative mitral regurgitation and who are determined to be at intermediate or high surgical risk for mitral valve repair, as assessed by the site's multidisciplinary heart team.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CardioMech MVRS
Time frame: 30 days
Time frame: 30 days
This study is active but is not currently recruiting participants.
Notify MeCardioMech AS
Industry
Early Feasibility Study of the CardioMech Mitral Valve Repair System (MVRS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07244939
Cardiovascular Diseases, Heart Diseases
São Paulo, Brazil
View Trial DetailsNCT07798037
Cardiovascular Diseases, Heart Diseases
Athens, Greece
View Trial DetailsNCT04375332
Cardiovascular Diseases, Heart Diseases
San Francisco, California, United States
View Trial DetailsNCT04430075
Cardiovascular Diseases, Heart Diseases
Vienna, Austria
View Trial Details